AU2018322756B2 - Composition comprising suplatast tosilate - Google Patents

Composition comprising suplatast tosilate Download PDF

Info

Publication number
AU2018322756B2
AU2018322756B2 AU2018322756A AU2018322756A AU2018322756B2 AU 2018322756 B2 AU2018322756 B2 AU 2018322756B2 AU 2018322756 A AU2018322756 A AU 2018322756A AU 2018322756 A AU2018322756 A AU 2018322756A AU 2018322756 B2 AU2018322756 B2 AU 2018322756B2
Authority
AU
Australia
Prior art keywords
film
release
tablet
suplatast
suplatast tosilate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2018322756A
Other languages
English (en)
Other versions
AU2018322756A1 (en
Inventor
John Bondo Hansen
Bent HØJGAARD
Mikael Søndergård Thomsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solural Pharma ApS
Conrig Pharma ApS
Original Assignee
Solural Pharma ApS
Conrig Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solural Pharma ApS, Conrig Pharma ApS filed Critical Solural Pharma ApS
Publication of AU2018322756A1 publication Critical patent/AU2018322756A1/en
Application granted granted Critical
Publication of AU2018322756B2 publication Critical patent/AU2018322756B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018322756A 2017-08-29 2018-08-28 Composition comprising suplatast tosilate Expired - Fee Related AU2018322756B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17188229.3 2017-08-29
EP17188229 2017-08-29
PCT/EP2018/073123 WO2019042995A1 (en) 2017-08-29 2018-08-28 COMPOSITION COMPRISING SUPLATAST TOSILATE

Publications (2)

Publication Number Publication Date
AU2018322756A1 AU2018322756A1 (en) 2020-03-19
AU2018322756B2 true AU2018322756B2 (en) 2023-10-19

Family

ID=59745229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018322756A Expired - Fee Related AU2018322756B2 (en) 2017-08-29 2018-08-28 Composition comprising suplatast tosilate

Country Status (8)

Country Link
US (1) US11819482B2 (enExample)
EP (1) EP3675831A1 (enExample)
JP (1) JP7330948B2 (enExample)
KR (1) KR20200045496A (enExample)
CN (1) CN111032021A (enExample)
AU (1) AU2018322756B2 (enExample)
CA (1) CA3073866A1 (enExample)
WO (1) WO2019042995A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002370968A (ja) * 2001-06-12 2002-12-24 Towa Yakuhin Kk 薬物含有徐放性顆粒およびそれを含む錠剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556737A (en) 1983-03-11 1985-12-03 Taiho Pharmaceutical Company Limited Sulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the same
JPS6168455A (ja) 1984-09-12 1986-04-08 Taiho Yakuhin Kogyo Kk アミド化合物
JPH0370698A (ja) 1989-08-11 1991-03-26 Naomasa Nomura 頭部回転式高性能飛行機
WO1995003052A1 (en) 1993-07-22 1995-02-02 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
EP0886519A1 (en) 1996-11-01 1998-12-30 Ilex Oncology, Inc. Sustained release formulation containing dfmo
JP2002179554A (ja) 1997-09-05 2002-06-26 Takeda Chem Ind Ltd 医 薬
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
EP1107740A4 (en) 1998-08-25 2002-03-06 Platt Chris SLOW RELEASE TABLET COMPRISING NAPROXENE AND PSEUDOEPHEDRINE
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7138140B2 (en) * 2001-04-16 2006-11-21 Taiho Pharmaceutical Co., Ltd. Suplatast tosilate crystals
WO2002087549A1 (fr) 2001-04-25 2002-11-07 Taisho Pharmaceutical Co., Ltd. Comprimes a liberation prolongee du type a unites multiples
US20050171119A1 (en) * 2002-01-09 2005-08-04 Ucb, S.A. Pharmaceutical formulations with modified release
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
EP1591109B1 (en) 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
JP4498101B2 (ja) 2004-11-04 2010-07-07 大鵬薬品工業株式会社 頭痛の予防及び／または治療剤
WO2007001058A1 (ja) * 2005-06-27 2007-01-04 Juntendo Educational Foundation ヘルペスウイルス由来疼痛治療剤
JP2006335771A (ja) 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
JP5489719B2 (ja) 2006-11-17 2014-05-14 スパーナス ファーマシューティカルズ インコーポレイテッド トピラマートの徐放性配合物
WO2008119988A1 (en) * 2007-03-30 2008-10-09 Cardoz Ab New combination for use in the treatment of inflammatory disorders
CN101028254B (zh) * 2007-04-05 2010-05-19 合肥合源医药科技股份有限公司 一种多索茶碱缓释制剂及其制备方法
CN101590022A (zh) * 2008-05-29 2009-12-02 焦作平光制药有限责任公司 甘氨酸茶碱钠缓释片及其制备方法
JP2011246454A (ja) 2010-04-27 2011-12-08 Daiichi Sankyo Healthcare Co Ltd 安全な免疫抑制剤または免疫異常抑制剤組成物
CN102210688B (zh) 2011-05-24 2013-04-03 赛乐医药科技(上海)有限公司 复方甲氧那明的速释-缓释制剂
WO2016192680A1 (en) * 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
WO2017032384A1 (en) 2015-08-25 2017-03-02 Conrig Pharma Aps Compound and use in the treatment of cough
DK3393463T3 (da) * 2015-12-23 2021-04-26 Conrig Pharma Aps Suplatast-tosilat til behandling af hoste forbundet med interstitiel lungesygdom

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002370968A (ja) * 2001-06-12 2002-12-24 Towa Yakuhin Kk 薬物含有徐放性顆粒およびそれを含む錠剤

Also Published As

Publication number Publication date
EP3675831A1 (en) 2020-07-08
WO2019042995A1 (en) 2019-03-07
AU2018322756A1 (en) 2020-03-19
JP7330948B2 (ja) 2023-08-22
JP2020532548A (ja) 2020-11-12
CA3073866A1 (en) 2019-03-07
CN111032021A (zh) 2020-04-17
US20200230083A1 (en) 2020-07-23
KR20200045496A (ko) 2020-05-04
US11819482B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
RU2428176C2 (ru) Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
US20090263478A1 (en) Carvedilol forms, compositions, and methods of preparation thereof
KR20100119539A (ko) 다이펜하이드라민을 포함하는 경구 분해성 정제
BR112012028035A2 (pt) forma de dosagem e formulação de liberação imediata, e, uso das mesmas
AU2013344281A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
US12161761B2 (en) Extended release multiparticulates of ranolazine
EP2601936A1 (en) Compressed composition
US10188610B2 (en) Prolonged-release diphenidol composition
US20090028935A1 (en) Carvedilol forms, compositions, and methods of preparation thereof
AU2018322756B2 (en) Composition comprising suplatast tosilate
US10792257B2 (en) Pharmaceutical compositions comprising safinamide
EP3796908B1 (en) Controlled release propiverine formulations
WO2021197451A1 (zh) 一种替格瑞洛的多元制剂
US9173845B2 (en) Controlled release pharmaceutical compositions of milnacipran
WO2011075912A1 (zh) 治疗帕金森氏症的医药组合物及其制备方法
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
WO2011027322A1 (en) Extended release dosage form containing olopatadine for oral administration
JP5819680B2 (ja) 塩酸アンブロキソールの小型徐放性製剤
CN107616969B (zh) 迅速崩解的吡仑帕奈片剂药物组合物
KR20040005257A (ko) 방출제어형 약제학적 조성물
US20230330076A1 (en) Controlled release formulations of flavoxate and process for preparation thereof
KR20180002437A (ko) 독실아민 및 피리독신을 포함하는 약제학적 복합 제제
JP2015061830A (ja) 塩酸アンブロキソールの小型徐放性製剤

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee